1 Introduction --;1. Introduction --;References --;2 Prodrugs in Cancer Chemotherapy --;1. Introduction --;2. Uses of Prodrugs in Cancer Chemotherapy --;3. Clinical Use of Prodrugs --;References --;3 Factors Influencing Tumor-Selective Localization of Antibody Conjugates --;1. Introduction --;2. Tumor Physiology --;3. Properties of the Monoclonal Antibody Vector --;4. Tumor Antigens --;5. Manipulation of Tumor Antigenic Expression --;6. Evaluation of Antigenic Targets for ADEPT --;7. In VitroCell Culture Problems --;8. Unforeseen Problems of Specificity --;References --;4 Enzymes and Prodrugs Used for ADEPT --;1. Introduction --;2. Enzymes and Prodrugs Used for ADEPT --;3. Conclusions --;References --;5 The Design and Synthesis of Prodrugs for Antibody-Directed Enzyme Prodrug Therapy (ADEPT) --;1. Introduction --;2. Prodrugs Used in ADEPT --;3. Summary --;References --;6 Preparation and Purification of Antibody-Enzyme Conjugates for Therapeutic Applications --;1. Introduction --;2. Production of Antibody Fragments --;3. Chemical Coupling of Antibodies to Enzymes --;4. Alternatives to Chemical Coupling --;5. Purification of Conjugates --;6. Postpurification Modifications --;7. Future Developments --;References --;7 Phage Technology for Producing Antibody-Enzyme Fusion Proteins --;1. Introduction --;2. Antibody-Targeted Cancer Therapy --;3. Potential of Engineered Antibodies for Therapy --;4. Single-chain Fv Antibodies --;5. The Phage System --;6. Target Antigens --;7. Engineered Antibody-Enzyme Fusion Proteins in ADEPT --;8. Practical Considerations --;9. Conclusions --;References --;8 Early Clinical Studies with ADEPT --;1. Introduction --;2. Initial Clinical Studies --;3. Second Clinical Study --;4. Conclusions --;References --;9 Gene-Directed Enzyme Prodrug Therapy (GDEPT) of Cancer --;1. Introduction --;2. Why GDEPT? --;3. Enzymes and Prodrugs Used for GDEPT --;4. Conclusions --;References --;Enzymes and Prodrugs Proposed for Cancer Therapy --;References.
یادداشتهای مربوط به خلاصه یا چکیده
متن يادداشت
Antibody-directed enzyme prodrug therapy (ADEPT) directly addresses the major problem in cancer chemotherapy-its lack of selectivity. ADEPT offers a novel field of opportunities in the therapy of systemic cancer and may be a major advance for the treatment of solid tumours. This book is the first to describe ADEPT in detail.
موضوع (اسم عام یاعبارت اسمی عام)
موضوع مستند نشده
Immunology.
موضوع مستند نشده
Internal medicine.
موضوع مستند نشده
Medicine.
رده بندی کنگره
شماره رده
RC271
.
A66
نشانه اثر
E358
1999
نام شخص به منزله سر شناسه - (مسئولیت معنوی درجه اول )